Awards Nomination 20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • ResearchBible
  • China National Knowledge Infrastructure (CNKI)
  • Scimago
  • Ulrich's Periodicals Directory
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • MIAR
  • Scientific Indexing Services (SIS)
  • Euro Pub
  • Google Scholar
Share This Page
Recommended Webinars & Conferences
Journal Flyer
Flyer image
Nanoparticles for treatment of Alzheimer′s disease
11th International Conference and Expo on Nanoscience and Molecular Nanotechnology
October 20-22, 2016 Rome, Italy

Massimo Masserini

University of Milano-Bicocca, Italy

Keynote: J Nanomed Nanotechnol


Alzheimer's Disease (AD) is a neurodegenerative disorder characterized by the β-amyloid (Aβ) peptide accumulation and deposition in the brain. Aβ alterations are thought to take place decades before the appearance of the first signs of dementia: This preclinical phase is considered the most promising period for successful disease-modifying therapies, which are still lacking. Since negatively charged lipids showed high binding affinity toward Aβ peptide and low-density lipoproteinreceptor was observed at the blood-brain barrier, we previously designed liposomes functionalized with phosphatidic acid and with a modified peptide derived from apolipoprotein-E (mApoE-PA-LIP) potentially able to enter the brain and disaggregate Aβ aggregates both in vitro and in vivo. We evaluated the possibility to use mApoE-PA-LIP for treatment of AD on different Tg rodent models of the disease, namely APP/PS1 or APP23 mice. The data obtained in vivo suggest that mApoE-PA-LIP is able either to promote the decrease of brain Aβ burden and the amelioration of memory impairment in �??old�?� Tg mice upon acute treatment, or to slow down brain Aβ accumulation and memory impairment in �??young�?� upon long term treatment. Together, these data indicate mApoE-PA-LIP as a new nanotechnological device potentially suitable for AD treatment.

Biography :

Massimo Masserini is Full Professor of Biochemistry and Moecular Biology at the School of Medicine, University Milano-Bicocca, Milano, Italy. He is Head of the Nanomedicine Center NANOMIB of the same university. He has published more than 150 articles in journals of Biochemistry, Neuroscience and Nanomedicine. He is CEO of AmypoPharma, a Spin-off Company of the University Milano-Bicocca aiming to carry nanoparticles for treatment of Alzheimer disease to the clinical phase.